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Objective: To identify a set of variables that could discriminate patients with adult-onset 
periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome 
from subjects with fever of unknown origin (FUO).
Methods: We enrolled 74 adults diagnosed with PFAPA syndrome according to 
the currently used pediatric diagnostic criteria and 62 additional patients with FUO. 
After having collected clinical and laboratory data from both groups, univariate and 
multivariate analyses were performed to identify the variables associated with PFAPA 
diagnosis. Odds ratio (OR) values, their statistical significance, and corresponding 95% 
confidence interval (CI) were evaluated for each diagnostic factor both at the  univariate 
and multivariate analyses. Diagnostic accuracy was evaluated by the area under 
receiver operating characteristic (ROC) curve, while the leave-one-out cross-validation 
procedure was used to ensure that the model maintains the same diagnostic power 
when applied to new data.
results: According to the multivariate analysis, the clinical variables that discriminated 
PFAPA patients were: fever episodes associated with cervical lymphadenitis (OR = 92; 
p  <  0.0001), fever attacks associated with erythematous pharyngitis (OR  =  231; 
p < 0.0001), increased inflammatory markers during fever attacks (OR = 588; p = 0.001), 
and the lack of clinical and laboratory signs of inflammation between flares (OR = 1202; 
p < 0.0001). These variables were considered for a diagnostic model which accounted 
for their OR values. The diagnostic accuracy of the proposed set of criteria corresponded 
to an area under ROC curve of 0.978 (95% CI 0.958–0.998), with a model sensitivity 
and specificity equal to 93.4% (95% CI 87.5–96.5%) and 91.7% (95% CI 82.8–96.7%), 
respectively.
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conclusion: we have provided herein a set of clinical diagnostic criteria for adult-onset 
PFAPA syndrome. Our criteria represent an easy-to-use diagnostic tool aimed at identify-
ing PFAPA patients among subjects with FUO with a high-predictive potential, as shown 
by its very high sensitivity and specificity.
Keywords: PFaPa syndrome, autoinflammatory disease, differential diagnosis, diagnostic criteria, adults, fever 
of unknown origin
inTrODUcTiOn
Periodic fever, aphthous stomatitis, pharyngitis, and cervical 
adenitis (PFAPA) syndrome belongs to the spectrum of multi-
factorial autoinflammatory diseases (AIDs) and is characterized 
by spontaneous flares of systemic inflammation characterized by 
fever and other clinical manifestations, especially cardinal signs 
described by the PFAPA acronym (1).
To date, the pathogenesis of this syndrome remains still 
obscure, but studies aimed at assessing immunological mecha-
nisms, also supported by therapeutic evidences (2, 3), have high-
lighted an abnormal interleukin-1 release in response to many 
environmental triggers, which associates PFAPA syndrome to 
other hereditary periodic fever disorders (4, 5). However, unlike 
other AIDs characterized by recurrent fever attacks, no genetic 
mutations have been clearly associated with PFAPA syndrome 
(6, 7).
In addition to fever (often achieving and overcoming 40°C), 
aphthous stomatitis, pharyngitis, and cervical adenitis, many 
other clinical manifestations may enrich the clinical framework 
of PFAPA patients, including abdominal pain, headache, nausea, 
skin manifestations, and arthralgia (1, 8–10). Inflammatory 
flares arise every 3–8 weeks with no premonitory symptoms and 
generally last 3–6  days. Patients are typically healthy between 
febrile episodes and the overall growth of children affected by 
this syndrome is not stunted (11, 12). Although during the last 
decades diagnosis of PFAPA syndrome has been relegated to chil-
dren aged under 5 years, increasing evidence has recently shown 
that the disease can also arise in older children as well as during 
adulthood (2, 3, 9, 10, 13–18). The treatment of PFAPA patients 
is based on intermittent corticosteroid administration, as patients 
are generally responsive to a single dose of a corticosteroid given 
at the onset of febrile flares (1, 12, 14, 19, 20).
No laboratory or instrumental tools are available to support 
the diagnosis of PFAPA syndrome, which is currently based on 
the fulfillment of clinical diagnostic criteria. In particular, to date, 
clinical criteria proposed by Marshall et al. in 1986 (21) and later 
modified by Thomas et al. in 1999 (11) represent the most used 
set of criteria in the clinical practice. However, these criteria are 
tailored on pediatric patients and their application on adults is 
categorically excluded by the first item that requires the presence 
of recurrent fever in patients under 5 years of age. In addition, the 
fifth item imposes the lack of normal growth and development for 
patients affected, which is not applicable to adult-onset PFAPA 
patients. In this context, Padeh et al. employed a further set of 
inclusion criteria valid for both children and adult patients (8). 
This set included the presence of monthly fever attacks, exudative 
tonsillitis, possibly oral ulcers, cervical lymph node enlargement, 
negative throat cultures, and failure of antibiotic treatment dur-
ing the acute episodes or as prophylactic treatment, while normal 
growth/development and a rapid response to a single corticos-
teroid administration were later added as further items (8, 22). 
However, to the best of our knowledge, no statistical procedures 
were employed to identify variables useful in discriminating 
PFAPA patients among subjects presenting with recurrent fever 
attacks. In addition, recent evidences have proved that erythema-
tous pharyngitis is more typical than sterile exudative pharyngitis 
in adult-onset PFAPA patients (10). Therefore, the need for a 
new set of diagnostic criteria for patients experiencing PFAPA 
syndrome during adulthood has prompted our group to evaluate 
a set of variables on both clinical and statistical basis that could 
discriminate such patients from subjects with fever of unknown 
origin (FUO).
MaTerials anD MeThODs
Patients
Seventy-four consecutive adult patients who had been referred 
to our Units from September 2007 to December 2016 because 
of recurrent fever attacks and other clinical manifestations con-
sistent with PFAPA syndrome were classified as suffering from 
adult-onset PFAPA syndrome (PFAPA group) according to the 
Marshall criteria modified by Thomas et al. (11, 21), which are 
the most frequently used diagnostic tool in the clinical practice. 
As this set of criteria is tapered on pediatric patients, the item 
requiring a disease onset before the age of 5 was neglected, while 
the item requiring a normal growth and development was retro-
spectively applied, as previously made in other studies (9, 10, 13). 
Two patients out of 74 were included in the PFAPA group despite 
the lack of symptom-free intervals. In both cases, the patients 
showed the resolution of fever and of cardinal symptoms as well 
as the normalization of acute phase reactants. Conversely, the sole 
arthralgia and myalgia persisted in both cases and were attributed 
to the presence of concomitant degenerative, not inflammatory 
musculoskeletal diseases.
Sixty-two additional adult subjects admitted in our Units 
between September 2016 and March 2017 for recurrent FUO 
were consecutively enrolled in the study as control group (con-
trol group). FUO diagnosis was based on the currently available 
diagnostic criteria (23). As for patients with adult-onset PFAPA 
syndrome, any specific disease related to fever or inflammatory 
manifestations had been ruled out at the time of enrollment 
in this study. The control group was included into a follow-up 
protocol aimed at early identify any sign or symptom potentially 
useful for a prompt specific diagnosis; patients were treated with 
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non-steroidal anti-inflammatory drugs or low-to-high dosage 
corticosteroids.
assessment Parameters
Each patient’s medical record was reviewed for demographic 
and clinical data. In particular, we looked for the age at disease 
onset, characteristics of the febrile pattern (peak temperature, 
duration of flares, frequency of fever episodes per year), clinical 
manifestations accompanying fever (oral and/or genital aphtho-
sis, exudative and/or erythematous pharyngitis, cervical and/or 
widespread lymphadenitis, abdominal pain, vomiting, diarrhea, 
thoracic pain, arthralgia, arthritis, myalgia, urticarial-like rash, 
maculopapular rash, erysipelas-like rash, erythematous rash, 
periorbital edema, conjunctivitis, asthenia, and headache), any 
increase of inflammatory markers (erythrocyte sedimentation 
rate and/or C-reactive protein and/or serum amyloid A) during 
attacks and the presence or absence of clinical manifestations 
and positive laboratory inflammatory markers during fever-free 
intervals.
None of the patients with adult-onset PFAPA syndrome showed 
upper respiratory infections, while the throat swab was negative 
in all cases presenting with pharyngitis or cervical lymphadeni-
tis. Both PFAPA group and control group patients underwent 
detailed laboratory and instrumental screening tests to rule out 
potential underlying diseases, such as infections, autoimmune 
diseases, and malignancies. In all patients enrolled, previous 
antibiotic therapies administered during flares did not change 
the progression of clinical manifestations. Monogenic periodic 
fever syndromes were ruled out by performing molecular analysis 
of MEFV, MVK, TNFRSF1A, and NLRP3 genes, respectively 
responsible for familial Mediterranean fever (FMF), mevalonate 
kinase deficiency, tumor necrosis factor receptor-associated 
periodic syndrome, and cryopyrin-associated periodic syndrome 
(CAPS). Moreover, neither PFAPA patients nor subjects included 
in the control group fulfilled clinical diagnostic criteria for FMF 
or CAPS as well as for Still’s disease, Schnitzler’s syndrome, and 
Behçet’s disease (24–33).
The study was approved by the local Ethics Committee of 
Azienda Ospedaliera Universitaria Senese, Siena (Italy) and each 
patient provided a written consent for both genetic testing and 
clinical data processing, in accordance with the Declaration of 
Helsinki.
statistical analysis
Descriptive statistics are expressed as mean and SD for quantita-
tive variables as well as frequency counts and percentages for 
quantitative binary variables.
Multivariate stepwise logistic regression analysis was per-
formed to identify, among all possible diagnostic factors (pre-
dictive variables), a statistically significant minimum subset of 
factors with the highest possible accuracy to establish a diagnosis 
of PFAFA syndrome. In the stepwise process, one independent 
variable was added to or removed from the discriminant model 
at each step, on the basis of maximum likelihood-ratio statistics. 
The process stops when no statistical significant variables can 
be more entered or removed. We used the leave-one-out (LOO) 
cross-validation procedure to ensure that the model maintains 
the same diagnostic power when applied to new data. LOO uses 
all available data to train and test model: it executes a number of 
training sessions equal to the sample size (N) and in each of them 
it classifies each patient (LOO testing case) in turn by using all 
other patients as training set.
Diagnostic accuracy was evaluated by the area under receiver 
operating characteristic (ROC) curve (AUC) along with its 95% 
confidence interval (95% CI). Model sensitivity and specificity 
together with their 95% CIs were also estimated by selecting a 
probability threshold giving comparable sensitivity and specific-
ity values, along with their 95% CIs. The Hosmer–Lemeshow 
goodness-of-fit test was used to evaluate model calibration, that 
is its prognostic ability.
Finally, the odds ratio (OR), its statistical significance, and 
corresponding 95% CI were evaluated for each diagnostic factor, 
taken singularly (univariate analysis), and for the model selected 
factors, taken together (multivariate analysis). The SPSS software, 
version 10, was used for all statistical computations, always con-
sidering a significance level of 95% (p value < 0.05).
resUlTs
Both patients with adult-onset PFAPA syndrome and subjects 
belonging to the control group experienced a disease onset over 
the age of 16. Specifically, the mean age at disease onset was 
26.55 ±  10.03  years for PFAPA patients and 27.94 ±  17.67 for 
those with FUO. Table 1 summarizes demographic and clinical 
features of patients enrolled.
Univariate analysis performed on patients with PFAPA 
syndrome and subjects with FUO recognized clinical variables 
positively or negatively associated with PFAPA syndrome by an 
OR significantly different from 1, i.e., with a 95% CI not including 
1.0. The results of univariate analysis are summarized in Table 2.
As reported in Table  3, according to multivariate analysis 
performed on the two groups of patients, clinical variables that 
showed a statistical significant (p < 0.05) discriminant power to 
identify PFAPA patients were: recurrent fever accompanied by 
cervical lymphadenitis (OR = 92), recurrent fever with concomi-
tant erythematous pharyngitis (OR =  231), increased inflam-
matory markers during attacks (OR = 588), and symptom-free 
intervals corresponding to the lack of clinical manifestations and 
laboratory abnormalities between flares (OR = 1,202). These vari-
ables were then considered for a diagnostic model that accounts 
for their OR values. In particular, the occurrence of symptom-
free intervals and the increase of inflammatory markers during 
attacks, which have higher OR values, represent mandatory items 
in the proposed diagnostic model. Conversely, on the basis of 
their lower OR values, only one between fever associated with 
erythematous pharyngitis and fever with cervical lymphadenitis 
is required for the diagnosis of PFAPA syndrome. Table 4 shows 
the resulting set of criteria proposed in this study.
The diagnostic accuracy of the proposed diagnostic criteria 
corresponded to an AUC of 0.978 (95% CI 0.958–0.998), with 
sensitivity and specificity equal to 93.4% (95% CI 87.5–96.5%) 
and 91.7% (95% CI 82.8–96.7%), respectively. Figure 1 represents 
the ROC curve assessing the performance of the criteria for our 
PFAPA patients and the control group with FUO.
TaBle 1 | Demographic and clinical features of patients diagnosed with periodic 
fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome 
(PFAPA group) and patients with fever of unknown origin (control group).
PFaPa group control group
Age (years) 34.00 ± 11.86 40.56 ± 16.45
Males (%)/females (%) 48 (64.9)/26 (35.1) 23 (37.1)/39 (62.9)
Age at disease onset (years) 26.55 ± 10.03 27.94 ± 17.67
Mean temperature at attacks (°C) 39.31 ± 0.92 38.9 ± 1.02
Attacks per year 15.2 ± 8.44 9.45 ± 7.03
Duration of flares
≤2 days 2 (2.7%) 14 (22.6%)
3–5 days 46 (62.2%) 12 (18.2%)
6–9 days 9 (12.2%) 8 (12.9%)
≥10 days 11 (14.9%) 22 (35.5%)
PFaPa cardinal symptoms during attacks
Pharyngitis 70 (94.6%) 39 (62.9%)
Cervical lymphadenitis 61 (82.4%) 14 (22.6%)
Oral aphthosis 48 (64.9%) 21 (33.9%)
Other associated symptoms during attacks
Generalized lymphadenitis 4 (5.4%) 14 (22.6%)
Asthenia 62 (83.8%) 51 (82.3%)
Abdominal pain 33 (44.6%) 20 (32.3%)
Diarrhea and/or vomiting 16 (21.6%) 13 (21%)
Thoracic pain 13 (17.6%) 24 (38.7%)
Arthralgia 53 (71.6%) 42 (67.7%)
Arthritis 11 (14.9%) 16 (25.8%)
Myalgia 47 (63.5%) 37 (59.7%)
Urticaria-like rash 4 (5.4%) 10 (16.1%)
Erythematous rash 9 (12.2%) 0 (0.0%)
Erysipelas-like rash 0 (0.0%) 3 (4.8%)
Maculo-papular rash 3 (4.1%) 9 (14.5%)
Periorbital edema 6 (8.1%) 5 (8.1%)
Conjunctivitis 8 (10.8%) 18 (29%)
Headache 43 (58.1%) 37 (59.7%)
Genital aphthosis 3 (4.1%) 2 (3.2%)
increased inflammatory 
markers during attacks
72 (97.3%) 46 (74.2%)
symptom-free intervals 72 (97.3%) 33 (53.2%)
Quantitative data are referred as mean ± SD values; qualitative data are reported as 
frequency counts and percentages.
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DiscUssiOn
Despite the increasing evidence on the possible delayed onset of 
PFAPA syndrome during adulthood, current diagnostic criteria 
are tailored on pediatric patients (34) and their application on 
adults requires specific adjustments not yet validated. On this 
basis, we looked for clinical variables that can identify patients 
with adult-onset PFAPA syndrome among patients presenting 
with FUO. Therefore, we analyzed the occurrence of inflamma-
tory features in patients with a clinical picture consistent with 
adult-onset PFAPA syndrome, being excluded all the known 
causes of recurrent fever, as well as in patients consecutively 
visited in our Units because of FUO during a 6-month period. 
Multivariate analysis allowed to identify a set of clinical variables 
capable of discriminating adult-onset PFAPA patients. These 
variables were then rearranged into a diagnostic model in which 
items with a higher OR were considered mandatory for the 
diagnosis of PFAPA, while just one out of the two variables with 
a lower OR value had to be fulfilled.
Noteworthy, these proposed diagnostic criteria should be 
applied after having ruled out the known causes of fever in terms 
of infective, autoimmune, and neoplastic diseases. Monogenic 
AIDs should be also excluded on the basis of clinical presenta-
tion, as required by the clinical classification criteria recently 
proposed by Federici et al. to drive genetic analysis for patients 
with periodic fevers (35). According to Federici et al., we have also 
reported that the diagnosis of monogenic AIDs in adulthood is 
not unworkable when patients’ symptoms are carefully classified 
(36, 37). Therefore, a correct evaluation of the patients’ clinical 
picture integrated by familiar and laboratory data may allow the 
identification of adult-onset monogenic AIDs by specifically 
performing genetic testing. In addition to this, specific clinical 
diagnostic and classification criteria, when available, should also 
be applied to preventively recognize both monogenic (i.e., FMF 
and CAPS) and multifactorial AIDs (i.e., Behçet’s disease, Still’s 
disease, and Schnitzler’s disease) (24–33). Moreover, our present 
criteria should not be applied in patients with positive throat swab 
during fever episodes and in patients responsive to antibiotics, as 
for previous diagnostic and classification criteria (11, 22).
Among the cardinal signs of PFAPA syndrome, the occurrence 
of recurrent fever with erythematous pharyngitis represented 
the variable most strongly associated with diagnosis of PFAPA 
syndrome in adulthood, while exudative pharyngitis and oral 
aphthosis during attacks were not included in the model. 
Accordingly, we had previously found that the exudative form 
of pharyngitis is almost rare in patients with a delayed onset of 
PFAPA syndrome (9, 10), while univariate analysis performed in 
this study even highlights a protective role of exudative pharyngi-
tis against the diagnosis of PFAPA syndrome, further remarking 
a less important role of this clinical manifestation in adults. In 
relation to lymph node involvement, the specific observation 
of cervical lymphadenitis was strongly correlated to PFAPA 
syndrome both when considered individually and at the overall 
multivariate assessment. Conversely, at the univariate analysis, 
generalized lymphadenitis represented a variable tending to 
exclude the diagnosis of PFAPA syndrome in adults.
Regarding oral aphthosis, although significantly discriminant 
when considered singularly, it was not included into the multivari-
ate model as its diagnostic information resulted to be absorbed 
by “recurrent fever accompanied by erythematous pharyngitis” 
and “symptom-free intervals.” Therefore, most patients with oral 
aphthosis also presented at least one out of these two variables 
included in the model, thus minimizing the diagnostic value 
of oral aphthosis as an additional item. Interestingly, according 
with our results, Padeh had already suggested oral ulcers just 
as “possible” among the classification items proposed in 2005 
(22). Furthermore, other authors have also highlighted that oral 
aphthosis is less frequently encountered in adult-onset PFAPA 
patients than among children (9, 11, 14). These observations seem 
to corroborate that aphthous stomatitis, although important for 
clinical evaluation, does not necessarily have to be included for 
diagnostic purposes in adults.
In relation to non-cardinal symptoms, beyond generalized lym-
phadenitis, also thoracic pain, conjunctivitis, maculopapular, and 
urticarial-like skin rash appeared to be protective factors against 
PFAPA diagnosis when considered individually. Consequently, the 
TaBle 4 | Clinical diagnostic criteria resulting from the multivariate analysis.
Diagnostic criteria for adult-onset periodic fever, aphthous stomatitis, 
pharyngitis, and cervical adenitis (PFaPa) syndrome
Recurrent fever accompanied by
 (a) Erythematous pharyngitis  
and/or
 (b) Cervical lymphadenitis
Increased inflammatory markers during attacks
Symptom-free intervals
Diagnostic items accounted for their odds ratio (OR) values: variables with a higher 
OR value (increased inflammatory markers during attacks and symptom-free intervals) 
were established as mandatory in the final diagnostic model; conversely, on the basis 
of a lower OR value, only one item between erythematous pharyngitis during fever and 
cervical lymphadenitis during fever is required for the diagnosis of PFAPA syndrome. 
These diagnostic criteria should be applied on patients aged at least 16 years and after 
having excluded infective, autoimmune, and neoplastic diseases as well as monogenic 
autoinflammatory diseases (AIDs) and febrile polygenic AIDs. In addition, throat swab 
performed during fever have to be negative and antibiotic therapy ineffective.
TaBle 3 | Estimations derived from multivariate logistic regression analysis 
performed on adult periodic fever, aphthous stomatitis, pharyngitis, and cervical 
adenitis (PFAPA) patients and patients with fever of unknown origin, representing 
the control group.
clinical variable p-Value Or 95% ci
Erythematous pharyngitis <0.0001 231 14.463–3,715.288
Cervical lymphadenitis <0.0001 92 8.865–953.279
Increased inflammatory markers 
during attacks
0.001 588 3,534.3–40,879.463
Symptom-free intervals <0.0001 1202 12.631–27,937.885
CI, confidence interval; OR, odds ratio.
TaBle 2 | Results of univariate logistic regression analysis performed on adult-onset periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 
patients and subjects with fever of unknown origin by evaluating clinical manifestations described in both groups.
clinical variable p-Value sensitivity (%) specificity (%) Or 95% ci
Age 0.010 47.5 81.1 0.968 0.944–0.992
Age at onset 0.591 1.7 98.6 0.994 0.971–1.017
Frequency of flares 0.001 51.1 81.2 1.108 1.046–1.174
Duration of flares
≤2 days 0.003 23.0 97.1 0.099 0.021–0.455
3–5 days <0.0001 80.0 65.7 7.667 3.437–17.102
6–9 days 0.936 0.0 100 0.959 0.345–2.664
≥10 days 0.006 37.3 84.3 0.314 0.136–0.721
Increased inflammatory markers during attacks 0.065 11.5 97.3 4.696 0.909–24.268
Symptom-free intervals <0.0001 45.9 97.3 30.545 6.867–135.878
Oral aphthosis 0.001 65.6 64.9 3.516 1.726–7.166
Pharyngitis 0.010 64.5 86.5 1.943 1.169–3.229
Erythematous pharyngitis <0.0001 91.9 78.4 41.325 14.194–120.315
Exudative pharyngitis 0.005 27.4 91.9 0.234 0.086–0.637
Laterocervical lymphadenitis <0.0001 76.3 82.4 15.082 6.463–35.199
Generalized lymphadenitis 0.006 22.6 94.6 0.196 0.061–0.631
Asthenia 0.813 0.0 100 1.114 0.454–2.736
Abdominal pain 0.163 67.2 44.6 1.650 0.816–3.337
Diarrhea/vomiting 0.965 0.0 100 1.019 0.446–2.326
Thoracic pain 0.006 39.3 82.4 0.329 0.149–0.723
Arthralgia 0.624 0.0 100 1.202 0.577–2.504
Arthritis 0.104 26.2 85.1 0.491 0.208–1.158
Myalgia 0.647 0.0 100 1.176 0.588–2.354
Skin rash 0.531 0.0 100 0.776 0.350–1.718
Urticaria-like rash 0.047 16.4 94.6 0.291 0.087–0.982
Erythematous rash 0.999 0.0 100 NE 0.000–NE
Maculo-papular rash 0.041 14.8 95.9 0.244 0.063–0.946
Erysipelas-like rash 0.999 4.9 100 0.000 0.000–NE
Periorbital edema 0.993 0.0 100 1.006 0.292–3.469
Conjunctivitis 0.009 29.0 89.2 0.296 0.119–0.741
Headache 0.764 0.0 100 0.900 0.451–1.795
Genital aphthosis 0.787 0.0 100 1.286 0.208–7.952
NE, not evaluable; CI, confidence interval; OR, odds ratio.
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observation of these manifestations in patients with a suspected 
PFAPA syndrome should call for caution before assigning the diag-
nosis. In addition, univariate analysis shows that PFAPA syndrome 
is mostly connected with a fever duration ranging between 2 and 
5 days, while fever attacks lasting less than 48 h and longer than 
10 days should point to other diagnoses than PFAPA syndrome.
Although results obtained by univariate analysis are clinically 
interesting and potentially useful to identify or exclude adult-
onset PFAPA syndrome, we aimed at creating a set of diagnostic 
criteria easy to be applied in the clinical practice and reproducible 
for further studies. Therefore, we deliberately avoided a longer 
list of diagnostic items as well as concomitant exclusion criteria, 
without decreasing the predictive potential of the model. Indeed, 
as demonstrated by the very high level of sensitivity and specific-
ity obtained at ROC analysis, 93.4% of all patients fulfilling the 
diagnostic criteria would be correctly identified as having PFAPA 
syndrome and only 8.3% (100% −  specificity) would be incor-
rectly classified as PFAPA patients.
FigUre 1 | Receiver operating characteristic (ROC) curve obtained for adult 
periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 
patients and subjects with fever of unknown origin as control group. The area 
under curve is of 0.978 (95% CI 0.958–0.998), corresponding to sensitivity of 
93.4% (95% CI 87.5–96.5%) and specificity of 91.7% (95% CI 82.8–96.7%) 
for the proposed diagnostic model.
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In our casuistry, a male preponderance was observed among 
patients with adult-onset PFAPA syndrome, while the number of 
females was higher in the control group. Looking at the past data 
on adult-onset PFAPA syndrome, a gender imbalance was not 
clearly observed as the male/female ratio was 1 according to a 
review evaluating all the cases published until 2015 (38). However, 
more recently, we have already reported 30 patients characterized 
by a male preponderance (9). As this trend has been confirmed 
again in this study, the male preponderance could represent a 
non-random finding. Nevertheless, future observational studies 
are required to clarify whether the higher number of males is a 
stochastic event related to the consecutive enrollment of patients 
or a specific feature of the disease.
Of note, we did not take into account the complete response 
to a single dose of corticosteroid as a possible diagnostic item 
to provide a set of criteria immediately applicable at the first 
clinical assessment, also in patients never treated with steroids. 
In addition, the complete resolution of flares after a single-steroid 
administration has proved to be less pronounced in adults than 
among pediatric patients. In this regard, we have recently high-
lighted that 98.8% of 85 pediatric PFAPA patients and only 88.2% 
out of 17 adult patients with PFAPA syndrome experienced total 
resolution of flares after a single-corticosteroid administration 
(10). Since this is probably explained by inadequate corticoster-
oid dosages in adults, ad hoc dosage trials should be conducted 
on late-onset PFAPA patients before including this variable as an 
additional diagnostic item.
Although we performed genetic testing in all patients to 
exclude subjects carrying mutations in genes related to the 
most frequent monogenic AIDs, we did not perform a testing 
for myeloid restricted somatic mutations that have recently been 
described in adult patients and could explain autoinflammatory 
manifestations in some cases (39–41). This represents a potential 
limit of the genetic screening strategy adopted in our cohort of 
patients. Also, the sample size of our study is relatively small due 
to the rarity of adult-onset PFAPA syndrome. Nevertheless, we 
have reported herein the largest cohort of patients ever described, 
adequate for performing a reliable statistic computation aimed at 
creating diagnostic criteria.
Our diagnostic criteria have been tested on adult patients 
and should be applied only to subjects aged at least 16  years. 
Their ability in differentiating adult-onset PFAPA patients from 
patients with late-onset monogenic AIDs could be tested in 
future studies.
In conclusion, we provide a set of clinical diagnostic criteria 
focused on adult patients presenting with suspected adult-onset 
PFAPA syndrome. They have been designed as an easy-to-use 
diagnostic tool aimed at identifying PFAPA patients from sub-
jects with FUO with a high-predictive potential as shown by its 
very high sensitivity and specificity.
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